Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Bayer Yakuhin on May 26 launched Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC). In the PIII ARAMIS trial, the drug plus androgen deprivation therapy (ADT) delivered a median metastasis-free survival (MFS) of 40.4 months, showing a…
To read the full story
Related Article
- Nubeqa Filed for Metastatic Prostate Cancer in Japan: Bayer
March 14, 2022
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





